DEXDOMITOR 0.1 Offers Precise Dosing for Small Dogs and Cats

Treating small dogs and cats demands precision. That’s why we’ve developed DEXDOMITOR 0.1, a convenient solution to sedation and preanesthetic protocols in dogs weighing less than 20 lb and cats less than 7 lb.

DEXDOMITOR 0.1 delivers all the advantages of sedation you expect from DEXDOMITOR® (dexmedetomidine), such as simplified procedures,1,2 reduced risk for patients and staff,2,3 and improved client satisfaction.4 But because it’s less concentrated, DEXDOMITOR 0.1 offers additional benefits for small dogs and cats, including:

  • More accurate dosing
  • Efficient and convenient drug administration without need for dilution
  • Decreased potential for dosing errors

Customer Experience Videos


The following graphic illustrates the difference between DEXDOMITOR 0.1 and DEXDOMITOR in the recommended preanesthesia dosage for a 6-lb Yorkshire terrier.

Difference between DEXDOMITOR 0.1 and DEXDOMITOR

The DEXDOMITOR 0.1 dose is 5x greater than the DEXDOMITOR dose, allowing for:

  • More precise dosing
  • No dilution
  • Confident administration

Dosing Based on Body Surface Area (BSA) Provides Predictable Effects.

BSA dosing is recommended for drugs with high selectivity and specificity such as dexmedetomidine.5

Since small dogs have a greater body surface area to body weight ratio, they require a higher dosage per unit of body weight (see chart).6

  • For small patients, dose volume with DEXDOMITOR (0.5 mg/mL) is low, with a potential for under-dosing or overdosing.
  • DEXDOMITOR 0.1 allows a larger dose volume for small dogs and cats—increasing accuracy, consistency and predictability.

Need Help Dosing?

The interactive DEXDOMITOR dosing calculator can help you determine the recommended sedation/analgesia and preanesthesia dosages for dogs and cats of all sizes.

Download Resources

Important Safety Information:

Do not use DEXDOMITOR or DEXDOMITOR 0.1 in dogs or cats, and ANTISEDAN in dogs, with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue. DEXDOMITOR and DEXDOMITOR 0.1 should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. As with all α2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists with DEXDOMITOR and DEXDOMITOR 0.1. The use of DEXDOMITOR and DEXDOMITOR 0.1 as a preanesthetic in dogs and cats significantly reduces the amount of induction and maintenance anesthetic requirements. Careful patient monitoring is necessary to avoid anesthetic overdose. Arrhythmias, bradycardia, apnea, emesis, convulsions, hypersalivation may occur with DEXDOMITOR and DEXDOMITOR 0.1 use. Severe dyspnea and respiratory crackles due to acute or delayed pulmonary edema could develop in cats. DEXDOMITOR and DEXDOMITOR 0.1 have not been evaluated for use in breeding, pregnant, or lactating dogs or cats; in dogs younger than 16 weeks of age or in cats younger than 12 weeks of age; or in geriatric dogs or cats. Occasional vomiting may occur with ANTISEDAN use. Rarely, a brief state of excitement or apprehensiveness may be seen in ANTISEDAN-treated dogs. Other potential side effects of α2-antagonists, such as ANTISEDAN, include hypersalivation, diarrhea, and tremors. See full Prescribing Information.


1 Vogelnest LT et al. The suitability of medetomidine sedation for intradermal skin testing in dogs. Vet Dermatol. 2000;11(4):285-290.
2 Scrivani PV et al. Restraint methods for radiography in dogs and cats. Compend Contin Educ Pract Vet. 1996;18(8):899-917.
3 Rodan l et al. AAFP and ISFM feline-friendly handling guidelines. J Feline Med Surg. 2011;13(5):364-375.
4 Karas AZ. Sedation and chemical restraint in the dog and cat. Clin Tech Small Anim Pract. 1999;14(1):15-26.
5 Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 1958;18:853-856.
6 Singer D. Size relationship of metabolic rate: oxygen availability as the “missing link” between structure and function. Thermochimica Acta. 2006;446(1-2):20-28.

DEXDOMITOR, DEXDOMITOR 0.1 and ANTISEDAN are trademarks owned by Orion Corporation and Orion Pharma. These products are developed and manufactured by Orion Corporation Orion Pharma Finland and distributed by Zoetis Inc. ©2014 Zoetis Inc. All rights reserved. June 2014. DEX-00059